23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Nurix Therapeutics, Inc. › 2025-2026

Nurix Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Nurix Therapeutics, Inc.’s Form 8-K, filed May 15, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 215Asset managers, any item
  • 1,232Fund votes
  • May 15, 2026Meeting date

Results at a glance

Meeting of May 15, 2026: 5 items on Nurix Therapeutics, Inc.’s Form 8-K, filed May 15, 2026: 3 elected · 2 approved.

Dissent

Significant dissent: 2 directors (25.8%, 20.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13F, 4.5%, as of September 30, 2026)

Explore Nurix Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Nurix Therapeutics, Inc.

These tallies are Nurix Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 15, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Nurix Therapeutics, Inc. — official shareholder meeting results, meeting held May 15, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Arthur T. Sands, M.D., Ph.D. 63,592,948---- 16,334,5703,819,495 80%Elected—
Elect Director: Roger Dansey, M.D. 79,607,489---- 320,0293,819,495 99.6%Elected—
Elect Director: Paul M. Silva 59,298,612---- 20,628,9063,819,495 74%Elected—
2. Ratification of Appointment of Independent Registered Public Accounting Firm 83,555,977166,39124,645 ---- 99.8%Approved—
3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers 72,458,9206,895,394573,204 --3,819,495 91%Approved—

Source: Nurix Therapeutics, Inc., Form 8-K, filed with the SEC on May 15, 2026 — read the filing on EDGAR.

How asset managers voted at the Nurix Therapeutics, Inc. 2025-2026 meeting

215 asset managers disclosed a vote on at least one Nurix Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Arthur T. Sands, M.D., Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 63,592,948WITHHELD: 16,334,570
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Arthur T. Sands, M.D., Ph.D.”): 63,592,948 for, 16,334,570 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 23,121,907 for, 4,366,423 withheld, 141,473 abstained.

FORWITHHOLD
FOR: 23,121,907ABSTAIN: 141,473WITHHOLD: 4,366,423
Largest asset managers voting on “Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.” at Nurix Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,167,8340 03,564,112Mixed
Vanguard5,404,4390 7,8000For
BlackRock4,833,2590 00For
T. Rowe Price2,265,1790 00For
ARK ETF Trust1,632,0380 00For
State Street1,528,3230 03,868For
MUTUAL FUND SERIES TRUST1,297,8930 025,571For
Charles Schwab922,6090 00For
Capital Group893,3270 00For
TIAA744,3450 00For
Dimensional00 0258,949Withhold
Equitable187,0380 063,470Mixed
Goldman Sachs211,1530 00For
Invesco170,3680 00For
QUANTITATIVE MASTER SERIES LLC164,6200 00For
Brighthouse65,1630 032,631Mixed
CARILLON SERIES TRUST00 88,1580Abstain
Nationwide50,5330 031,966Mixed
American Century00 077,991Withhold
Northern Trust70,7350 00For
Lincoln Financial66,6000 01,279For
Global X67,3740 00For
John Hancock30,5770 29,2980Mixed
AIG/SunAmerica00 058,276Withhold
Columbia Threadneedle56,1350 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Elect Director: Paul M. Silva

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 59,298,612WITHHELD: 20,628,906
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of Class III Directors: Paul M. Silva

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Paul M. Silva”): 59,298,612 for, 20,628,906 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 21,391,262 for, 6,097,061 withheld, 141,479 abstained.

FORWITHHOLD
FOR: 21,391,262ABSTAIN: 141,479WITHHOLD: 6,097,061
Largest asset managers voting on “Election of Class III Directors: Paul M. Silva” at Nurix Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,167,8340 03,564,112Mixed
Vanguard5,400,7510 7,8063,682For
BlackRock4,833,2590 00For
T. Rowe Price2,265,1790 00For
ARK ETF Trust1,632,0380 00For
State Street1,0300 01,531,161Withhold
MUTUAL FUND SERIES TRUST1,297,8930 025,571For
Charles Schwab922,6090 00For
Capital Group893,3270 00For
TIAA744,3450 00For
Dimensional00 0258,949Withhold
Equitable187,0380 063,470Mixed
Goldman Sachs211,1530 00For
Invesco170,3680 00For
QUANTITATIVE MASTER SERIES LLC164,6200 00For
Brighthouse65,1630 032,631Mixed
CARILLON SERIES TRUST00 88,1580Abstain
Nationwide50,5330 031,966Mixed
American Century00 077,991Withhold
Northern Trust00 070,735Withhold
Lincoln Financial00 067,879Withhold
Global X46,2040 021,170Mixed
John Hancock30,5770 29,2980Mixed
AIG/SunAmerica00 058,276Withhold
Columbia Threadneedle56,1350 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Elect Director: Roger Dansey, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 79,607,489WITHHELD: 320,029
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of Class III Directors: Roger Dansey, M.D.

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Roger Dansey, M.D.”): 79,607,489 for, 320,029 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 27,629,803 for.

FOR
FOR: 27,629,803
Largest asset managers voting on “Election of Class III Directors: Roger Dansey, M.D.” at Nurix Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,731,9460 00For
Vanguard5,412,2390 00For
BlackRock4,833,2590 00For
T. Rowe Price2,265,1790 00For
ARK ETF Trust1,632,0380 00For
State Street1,532,1910 00For
MUTUAL FUND SERIES TRUST1,323,4640 00For
Charles Schwab922,6090 00For
Capital Group893,3270 00For
TIAA744,3450 00For
Dimensional258,9490 00For
Equitable250,5080 00For
Goldman Sachs211,1530 00For
Invesco170,3680 00For
QUANTITATIVE MASTER SERIES LLC164,6200 00For
Brighthouse97,7940 00For
CARILLON SERIES TRUST88,1580 00For
Nationwide82,4990 00For
American Century77,9910 00For
Northern Trust70,7350 00For
Lincoln Financial67,8790 00For
Global X67,3740 00For
John Hancock59,8750 00For
AIG/SunAmerica58,2760 00For
Columbia Threadneedle56,1350 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

91% Approved · of votes cast

FOR 91%
FOR: 72,458,920AGAINST: 6,895,394

Prior year: 81.5% for (May 19, 2025 meeting) ▲ 9.9 pts

Details: description as filed, official tally, votes by 215 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

Nurix Therapeutics, Inc.’s own tally for this item (“3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 72,458,920 for, 6,895,394 against — passed, per its Form 8-K filed May 15, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 56 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at Nurix Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,167,8343,564,112 00Mixed
Vanguard5,412,22512 10For
BlackRock4,833,2590 00For
T. Rowe Price2,265,1790 00For
ARK ETF Trust1,632,0380 00For
State Street1,532,13160 00For
MUTUAL FUND SERIES TRUST1,323,4640 00For
Charles Schwab922,6090 00For
Capital Group0893,327 00Against
TIAA744,3450 00For
Dimensional258,9490 00For
Equitable250,5080 00For
Goldman Sachs211,1530 00For
Invesco0170,368 00Against
QUANTITATIVE MASTER SERIES LLC164,6200 00For
Brighthouse97,7940 00For
CARILLON SERIES TRUST88,1580 00For
Nationwide82,4990 00For
American Century077,991 00Against
Northern Trust70,7350 00For
Lincoln Financial67,8790 00For
Global X67,3740 00For
John Hancock59,8750 00For
AIG/SunAmerica58,2760 00For
Columbia Threadneedle56,1350 00For

Fund voting reports, all 56 managers: 22,923,931 for, 4,705,870 against, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 174 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at Nurix Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Redmile Group, LLC7,902,8080 00For
Deep Track Capital, LP5,198,3030 00For
Fidelity04,860,200 00Against
BAKER BROS. ADVISORS LP4,597,9160 00For
State Street3,448,82018,640 00For
BlackRock3,440,3940 00For
T. Rowe Price3,205,7180 00For
GENERAL ATLANTIC, L.P.00 3,032,1850Abstain
Vestal Point Capital, LP3,023,7160 00For
GEODE CAPITAL MANAGEMENT, LLC2,480,1620 00For
PICTET ASSET MANAGEMENT SA2,470,1940 00For
Rubric Capital Management LP2,447,6230 00For
PERCEPTIVE ADVISORS LLC2,307,2700 00For
Commodore Capital LP1,662,8710 00For
Trails Edge Capital Partners, LP1,412,3670 00For
Amova Asset Management Co., Ltd.1,186,4470 00For
Charles Schwab922,9420 00For
Capital Group0893,327 00Against
Nuveen780,3210 00For
Vanguard721,0730 00For
Northern Trust659,7927,040 00For
Affinity Asset Advisors, LLC628,4440 00For
Candriam S.C.A.00 534,2590Abstain
BRAIDWELL LP524,2960 00For
Handelsbanken Fonder AB492,2980 00For

Institutional-manager reports, all 174 managers: 56,682,464 for, 6,454,081 against, 473,485 withheld, 3,567,019 abstained, 352 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 83,555,977AGAINST: 166,391

Prior year: 99.9% for (May 19, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026.

Nurix Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 83,555,977 for, 166,391 against — passed, per its Form 8-K filed May 15, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 27,629,743 for, 60 against.

FOR
FOR: 27,629,743AGAINST: 60
Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public a” at Nurix Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,731,9460 00For
Vanguard5,412,2390 00For
BlackRock4,833,2590 00For
T. Rowe Price2,265,1790 00For
ARK ETF Trust1,632,0380 00For
State Street1,532,13160 00For
MUTUAL FUND SERIES TRUST1,323,4640 00For
Charles Schwab922,6090 00For
Capital Group893,3270 00For
TIAA744,3450 00For
Dimensional258,9490 00For
Equitable250,5080 00For
Goldman Sachs211,1530 00For
Invesco170,3680 00For
QUANTITATIVE MASTER SERIES LLC164,6200 00For
Brighthouse97,7940 00For
CARILLON SERIES TRUST88,1580 00For
Nationwide82,4990 00For
American Century77,9910 00For
Northern Trust70,7350 00For
Lincoln Financial67,8790 00For
Global X67,3740 00For
John Hancock59,8750 00For
AIG/SunAmerica58,2760 00For
Columbia Threadneedle56,1350 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Largest Nurix Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 103,405,813 shares outstanding at the time of that meeting.

Fund voting reports: top Nurix Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 5.54%
2Vanguard 5.23%
3BlackRock 4.67%
4T. Rowe Price 2.19%
5ARK ETF Trust 1.58%
6State Street 1.48%
7MUTUAL FUND SERIES TRUST 1.28%
8Charles Schwab 0.89%
9Capital Group 0.86%
10TIAA 0.72%
Institutional-manager reports: top Nurix Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Redmile Group, LLC 7.64%
2Deep Track Capital, LP 5.03%
3Fidelity 4.70%
4BAKER BROS. ADVISORS LP 4.45%
5State Street 3.35%
6BlackRock 3.33%
7T. Rowe Price 3.10%
8GENERAL ATLANTIC, L.P. 2.93%
9Vestal Point Capital, LP 2.92%
10GEODE CAPITAL MANAGEMENT, LLC 2.40%

Reported Nurix Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Nurix Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock8,925,642 8.63%Form 13F, quarter ended March 31, 2026
Redmile Group, LLC8,782,256 8.49%Schedule 13G, filed August 14, 2026
Vestal Point Capital, LP8,050,000 7.78%Schedule 13G, filed August 14, 2026
Deep Track Capital, LP7,736,455 7.48%Schedule 13G, filed August 14, 2026
Baker Bros. Advisors LP7,527,996 7.28%Schedule 13G, filed February 17, 2026
Rubric Capital Management LP7,227,778 6.99%Schedule 13G, filed August 14, 2026
Vanguard Group5,949,512 5.75%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)5,541,271 5.36%Form 13F, quarter ended March 31, 2026
State Street5,141,195 4.97%Form 13F, quarter ended March 31, 2026
Morgan Stanley4,881,069 4.72%Form 13F, quarter ended March 31, 2026

Percentages above are of 103,405,813 shares outstanding, as reported by Nurix Therapeutics, Inc. on its Form 10-Q dated April 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Nurix Therapeutics, Inc.'s shareholder meeting held May 15, 2026, in the 2025-2026 proxy season, 215 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,232 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — Nurix Therapeutics, Inc.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Nurix Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 15, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Nurix Therapeutics, Inc.’s 10-Q dated April 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Nurix Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Nurix Therapeutics (NRIX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/nurix-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.